D16F7

D16F7 is a monoclonal antibody specifically targeting vascular endothelial growth factor receptor-1 (VEGFR-1). It inhibits VEGFR-1 activation and homodimerization, thereby blocking downstream signal transduction induced by VEGF-A and placental growth factor (PlGF), but does not interfere with their binding to the receptor. This mechanism leaves intact the anti-angiogenic activity of the soluble form of VEGFR-1 (sVEGFR-1), which acts as a decoy receptor in the extracellular matrix. Preclinical data show that D16F7 effectively inhibits migration, invasiveness, and extracellular matrix invasion of tumor cells—including glioblastoma and melanoma—and reduces tumor growth and invasion in vivo, with increased survival in animal models. The antibody has shown promise as a novel therapeutic agent for glioblastoma, melanoma, and potentially other solid tumors, and warrants further investigation following humanization.[1][2][3]

Brand names

D16F7D-16F7D 16F7

Other names

D16F7D-16F7D 16F7